Kinnate Biopharma’s Q3 GAAP EPS falls short of estimates

Trending News 🌥️

Kinnate Biopharma ($NASDAQ:KNTE) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune diseases. Kinnate Biopharma’s Q3 GAAP EPS of -$0.70 misses estimates by $0.10. Kinnate Biopharma attributed the miss to higher-than-expected expenses related to its ongoing clinical trials. Despite the miss, Kinnate Biopharma reaffirmed its guidance for the full year.

Looking ahead, Kinnate Biopharma is focused on advancing its clinical trials and expanding its pipeline. Kinnate Biopharma is also working on improving its manufacturing processes to increase efficiency and reduce costs.

Earnings

The company lost $0.0 million in total revenue and $104.8 million in net income during the quarter ending June 30. Compared to the same period last year, Kinnate’s total revenue increased from $nan million to $0.0 million. Kinnate attributed the revenue shortfall to a number of factors, including clinical trial delays and lower-than-expected product sales. The company also said that it is continuing to invest in R&D and commercialization activities, which will impact its bottom line in the short term.

Looking ahead, Kinnate said it is focused on advancing its clinical programs and delivering on its commercial milestones. The company remains confident in its long-term prospects and is committed to delivering value for shareholders.

Share Price

On Friday, the stock opened at $8.7 and closed at $9.6, up 8.5% from the previous day’s close of $8.8. Despite the positive stock price movement, analysts remain concerned about the company’s long-term prospects.

VI Analysis

Kinnate Biopharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with genetically defined cancers. Kinnate Biopharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with genetically defined cancers. Kinnate Biopharma has a strong focus on developing targeted therapies for patients with genetically defined cancers.

VI Peers

The company’s lead product candidate, IPI-549, is an orally-available, small molecule inhibitor of PI3Kγ. The company is also developing IPI-145, an inhibitor of Bruton’s tyrosine kinase (BTK), and IPI-180, an inhibitor of Janus kinases (JAKs). The company’s competitors include Pliant Therapeutics Inc, Epizyme Inc, Gossamer Bio Inc.

– Pliant Therapeutics Inc ($NASDAQ:PLRX)

Pliant Therapeutics, Inc. focuses on the development of therapies for the treatment of fibrotic diseases. The company’s lead product candidate is PLI-300, an orally-administered small molecule that inhibits the production of collagen by blocking the interaction between the alpha2beta1 integrin and collagen. PLI-300 is in Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and scleroderma. The company was founded in 2015 and is headquartered in San Francisco, California.

– Epizyme Inc ($NASDAQ:GOSS)

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $990.28 million and its ROE is -1952.91%. Gossamer Bio’s lead product candidate, GB226, is a Phase 2b-ready monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.

Summary

Kinnate Biopharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer and other serious diseases. In addition, Kinnate is developing a portfolio of other small molecule IRAK4 inhibitors for the treatment of cancer and other inflammatory diseases. Kinnate’s focus on developing targeted therapies for cancer and other serious diseases makes it an attractive investment for those looking to invest in the biopharmaceutical industry.